Table 3. Risk for developing second... | American Society of Hematology

Table 3.

Risk for developing second primary infection-related solid tumors among reported HIV/AIDS⁺adult DLBCL survivors, SEER, 2000 to 2014

Second primary malignancy site	HIV/AIDS			No known HIV/AIDS*
Second primary malignancy site	Obs	SIR	95% CI	Obs	SIR	95% CI
Oropharynx/tonsil	<5	1.25	0.03-6.94	21	1.03	0.64-1.58
Stomach	0	0	NA	62	1.54†	1.18-1.98
Anus	14	68.34†	37.36-115	17	2.09†	1.22-3.34
Liver	<5	2.45	0.51-7.16	73	1.83†	1.43-2.30
Cervix uteri	<5	7.84	0.20-43.69	8	0.80	0.35-1.58

Second primary malignancy site	HIV/AIDS			No known HIV/AIDS*
Second primary malignancy site	Obs	SIR	95% CI	Obs	SIR	95% CI
Oropharynx/tonsil	<5	1.25	0.03-6.94	21	1.03	0.64-1.58
Stomach	0	0	NA	62	1.54†	1.18-1.98
Anus	14	68.34†	37.36-115	17	2.09†	1.22-3.34
Liver	<5	2.45	0.51-7.16	73	1.83†	1.43-2.30
Cervix uteri	<5	7.84	0.20-43.69	8	0.80	0.35-1.58

NA, not applicable.

Includes HIV/AIDS status NA, reflecting individual SEER registry practices.

Indicates 95% CI excludes 1.00, corresponding to 2-sided P < .05.